| Document Date: 2013-11-18 10:10:47
Open Document File Size: 181,33 KBShare Result on Facebook
City New York / Paris / / Company Genzyme / Sanofi / Oncology Sanofi Oncology / / Country France / / Event Company Listing Change / FDA Phase / / IndustryTerm therapeutic solutions / consumer healthcare / treatment solutions / healthcare / diabetes solutions / / MedicalCondition polycythemia vera / encephalopathy / cancer / myeloproliferative neoplasms / essential thrombocythemia / select solid tumors / diabetes / myelofibrosis / primary myelofibrosis / / Organization U.S. Food and Drug Administration / / Person Tal Zaks / / Position treating physician / integrated global healthcare leader / VP / Head of Development and Interim Head / / Product JAK2 / / Technology transplantation / therapeutic solutions / /
SocialTag |
PRESS RELEASE Sanofi Discontinues Clinical Development of Investigational JAK2 Agent Fedratinib (SAR302503) Paris, France – November 18, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the decision to ha